Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY
Neurological Oncology

Study Finds Bevacizumab Prolongs Life Among Patients With Deadly Brain Cancer

Share this Video
Copy Link
Published Online: Feb 19th 2014

Mayo Clinic neuro-oncologist Derek Johnson, M.D. discusses study that shows patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer.

Related Videos In Neurological Oncology
Neurological Oncology
Soffietti_T2.png
Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 2)

Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 2 of 2. Questions 1. What are the most promising agents targeting […]

Neurological Oncology
Soffietti_T1.png
Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 1)

Riccardo Soffietti (EAN Programme Committee; Chairman, Department of Neuro-Oncology, University and City of Health and Science Hospital, Turini, Italy) talks to us about the topic of the symposium he participated in entitled: Advances in molecular characterisation and personalised therapies in brain tumours. Part 1 of 2. Questions 1 What have been the most important recent […]

Neurological Oncology
Soffietti_T.png
EAN 2017 – Riccardo Soffietti Interview – Part 3

EAN Programme Committee Member, Prof. Riccardo Soffietti, provides his insights on neuro-oncology coverage at this year’s EAN congress. Part 3 of 3. View Part 1 here. View Part 2 here. Speaker disclosures: nothing to disclose in relation to this video interview. Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June […]

Trending In Neurological Oncology:

Riccardo Soffietti, EAN 2018 – Advances in personalised therapies for brain tumours (Part 2)
Neurological Oncology
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72